Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02108457 · ClinicalTrials.gov registry record
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
A clinical trial of Gynecologic Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 15
- Enrollment target
- 1
- Study location
NCT02108457 is a study of Gynecologic Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 15 participants, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02108457, a study of Gynecologic Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.
Conditions Studied
Interventions
- RADIATION [18F]Fluorothymidine (FLT) PET/CT Imaging
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-12-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02108457
The ClinicalTrials.gov registry entry for NCT02108457 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gynecologic Cancer appearing as the primary indexed condition, and to 1 intervention - of which [18F]Fluorothymidine (FLT) PET/CT Imaging is the first listed.
NCT02108457 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02108457 about?
NCT02108457 is a clinical study titled "[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers". The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. ...
What is the current status of trial NCT02108457?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2014-02. Estimated completion is 2016-12-21.
What conditions does trial NCT02108457 study?
This clinical trial studies the following conditions: Gynecologic Cancer.
What interventions are being tested in trial NCT02108457?
The interventions under investigation include: [18F]Fluorothymidine (FLT) PET/CT Imaging (RADIATION).
Who is sponsoring clinical trial NCT02108457?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02108457 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.